Oncology Drugs

Plus Therapeutics rebrands to Cerenome, signaling a major pivot to an integrated platform combining diagnostics, radiotherapeutics, and AI for CNS cancers.

Interim data for Pasithea Therapeutics' PAS-004 shows durable activity and superior safety, offering a new strategy for patients who have run out of options.

Positive Phase 3 data for BRUKINSA shows a 43% reduction in cancer progression, heralding a chemotherapy-free future for frontline mantle cell lymphoma.

A new partnership between Finland's Orion Pharma and India's Shilpa Medicare aims to bring a lower-cost cancer therapy to Europe, challenging a blockbuster drug.

A new 'radical collaboration' between top cancer centers is leveraging recent drug breakthroughs to develop combination therapies for pancreatic cancer's deadliest mutation.

Early results for AB Science's AB8939 show a 67% response rate in high-risk AML patients, offering a potential breakthrough where other treatments fail.

A landmark FDA decision on Trodelvy reshapes metastatic TNBC care, offering new hope while directly confronting deep-seated racial disparities in treatment.

Biotech innovator Ernexa Therapeutics launches a new CEO platform, betting that open communication can help it solve cell therapy's biggest challenge: cost.

A new license for C-Ray Therapeutics is more than a permit; it's a key move in Beijing's strategy to dominate the high-stakes radiopharmaceutical market.

Passage Bio finds a lifeline in a reverse merger with Remix Therapeutics, a rising RNA star. But what does this deal truly mean for shareholders and the future of cancer treatment?

A novel drug for glioblastoma enters a revolutionary trial, but the real story is the mission-driven company behind it, rewriting the rules of drug development.

Novartis is betting nearly $2 billion on Antares Therapeutics' novel platform to conquer historically 'undruggable' cancer targets, a move that could redefine oncology.

Early trial data for Verastem Oncology's VS-7375 reveals significant anti-tumor activity and a good safety profile, igniting hope for tough-to-treat cancers.

A Canadian biotech is developing a novel cancer drug. We look beyond the paid promotions to analyze the science, the strategy, and the high-stakes reality.

Haisco's massive licensing deal with Nuvectis for two high-potential drugs isn't just a transaction; it's a signal of a new world order in biotech.

Elevar Therapeutics' new trial for lirafugratinib aims for a tumor-agnostic label, a strategic move to redefine cancer treatment beyond a single indication.

For bladder cancer patients facing bladder removal, a novel therapy from Sweden offers new hope. A US trial expansion targets the most resistant cases.

Australian radiopharma innovator AdvanCell is planting its flag in Greater Boston with a new HQ and factory, a strategic move to scale its potent Lead-212 therapy.

bioAffinity Technologies' new gene-silencing therapy kills common skin cancer cells in lab studies while leaving healthy cells untouched, hinting at a future without scars.

A new prostate cancer drug is emerging from a powerful alliance. We deconstruct the strategic rationale behind the deal, revealing a model for the future.